USPTO serial 98413936
GORDIAN
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- EVANKO, PATRICIA MALESARDI
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with GORDIAN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South San Francisco, CA, US
South San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Tracy-Gene G. Durkin
Tracy-Gene G. Durkin Sterne, Kessler, Goldstein & Fox P.L.L.C.1101 K Street, N.W.10th FloorWashington, DC 20005Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, biological preparations, and cell- and gene-based therapy products to prevent and treat age-related cardiovascular disease, neurodegenerative disease, musculoskeletal disease, pulmonary disease, metabolic disease, diseases of the liver, macular degeneration and other ocular diseases, kidney disease, and cancer; pharmaceutical preparations, biological preparations, and cell- and gene-based therapy products to prevent and treat cardiovascular disease, neurodegenerative disease, musculoskeletal disease, pulmonary disease, metabolic disease, diseases of the liver, macular degeneration and other ocular diseases, kidney disease, and cancer | ACTIVE | — |
| 042 | Pharmaceutical and biological drug research and development services; research and development of pharmaceutical and biotechnology fields, namely, cell- and gene-based therapy research and development services; providing information about medical and scientific research on aging and complex multigenic diseases; providing information about medical and scientific research, namely, providing information on pharmaceutical drug, biological drug, and cell- and gene-based therapy research and development; providing scientific information on computational biology, machine learning, and bioinformatics | ACTIVE | — |
| 044 | Providing medical information on aging and complex multigenic diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 23, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 22, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 22, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 22, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 2, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 21, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 21, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 21, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 21, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 21, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 21, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 21, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 26, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 15, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 15, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 11, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 11, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 30, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 21, 2024 | NWAP | NEW APPLICATION ENTERED | — |